Podrobno

Izobraževanje oseb z multiplo sklerozo : diplomsko delo
ID Prijatelj Pelhan, Ana (Avtor), ID Jelenc-Krašovec, Sabina (Mentor) Več o mentorju... Povezava se odpre v novem oknu, ID Mažgon, Jasna (Komentor)

.pdfPDF - Predstavitvena datoteka, prenos (1,68 MB)
MD5: AD0AD63C5E7229BA265AA5494D2B8C19

Jezik:Slovenski jezik
Ključne besede:diplomska dela, andragogika, neformalno izobraževanje, vseživljenjsko učenje, ciljne skupine, multipla skleroza, zaposlovanje
Vrsta gradiva:Diplomsko delo
Tipologija:2.11 - Diplomsko delo
Organizacija:FF - Filozofska fakulteta
Kraj izida:Ljubljana
Založnik:[A. Prijatelj Pelhan]
Leto izida:2016
Št. strani:132 str.
PID:20.500.12556/RUL-112430 Povezava se odpre v novem oknu
UDK:374.7
COBISS.SI-ID:60965218 Povezava se odpre v novem oknu
Datum objave v RUL:22.10.2019
Število ogledov:2483
Število prenosov:327
Metapodatki:XML DC-XML DC-RDF
:
PRIJATELJ PELHAN, Ana, 2016, Izobraževanje oseb z multiplo sklerozo : diplomsko delo [na spletu]. Diplomsko delo. Ljubljana : A. Prijatelj Pelhan. [Dostopano 6 april 2025]. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=112430
Kopiraj citat
Objavi na:Bookmark and Share

Podobna dela

Podobna dela v RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Podobna dela v drugih slovenskih zbirkah:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Nazaj